Who has invested in OptiNose?

Fidelity Management and Research Company, Avista Capital Partners, Entrepreneurs Fund are named among the investors backing OptiNose.

OptiNose Funding: $37M Raised, Series D (2017)

OptiNose funding overview

OptiNose is a Biotech company based in Yardley. OptiNose has raised $37M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series D announced in May 2017. The round record for OptiNose runs through 2017; nothing later has been disclosed. Investors on record include Fidelity Management and Research Company, Avista Capital Partners, Entrepreneurs Fund. 3 distinct backers are named across the disclosed rounds.

OptiNose at a glance

Total raised: $37M
Latest round: Series D
Latest round date: May 2017
Industry: Biotech
Headquarters: Yardley
Notable investors: Fidelity Management and Research Company, Avista Capital Partners, Entrepreneurs Fund

Frequently asked about OptiNose funding

How much has OptiNose raised?: OptiNose has raised $37M in total disclosed funding across the rounds on record.
Who has invested in OptiNose?: Fidelity Management and Research Company, Avista Capital Partners, Entrepreneurs Fund are named among the investors backing OptiNose.
What was the latest OptiNose funding round?: The most recent disclosed round is a Series D, announced in May 2017.
Where is OptiNose based?: OptiNose is based in Yardley.
What sector does OptiNose operate in?: OptiNose is tracked under Biotech from Yardley, with $37M in disclosed funding.
When did OptiNose last raise?: The last disclosed OptiNose round closed in May 2017 at Series D.

OptiNose totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related Biotech companies in Yardley below to benchmark round size and investor mix.

OptiNose Funding: $37M Raised, Series D (2017)

OptiNose funding overview

OptiNose at a glance

Frequently asked about OptiNose funding

Companies related to OptiNose (23)

Browse related funding lists (3)